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INTRODUCTION
Leishmaniasis is caused by Leishmania species and has vis-
ceral, cutaneous, and mucocutaneous forms in humans. Vis-
ceral leishmaniasis (VL), also known as kala-azar, a dissemi-
nated and potentially fatal form, is endemic in areas of the trop-
ics, subtropics, and Southern Europe [1,2]. The disease can be 
observed sporadically at countries bordering Mediterranean 
basin, including Turkey [3]. 
Classic clinical features of VL include high fever, anorexia, 
hepatomegaly, marked splenomegaly, and pancytopenia due 
to severe involvement of reticuloendothelial system (RES) or-
gans, particularly the liver, spleen, and bone marrow. Labora-
tory tests usually show elevated inflammatory markers, marked 
eosinopenia, a relative lympho-monocytosis, hypergamma-
globulinemia with hypoalbuminemia, and occasionally evi-
dence of liver damage with raised liver enzymes [1,2]. 
Diagnosis of leishmaniasis is based on demographic, clini-
cal, and laboratory findings. Definite diagnosis requires dem-
onstration of the parasite either histologically in relevant tis-
sues or with Leishmania-specific immunologic tests [1]. How-
ever, diagnosis could be challenging in sporadic cases and of-
ten delayed, as the main clinical presentation is often identical 
to other infectious and non-infectious diseases. Furthermore, 
some of VL manifestations are associated with immune respon-
ses of the host to Leishmania that mimic autoimmune diseases 
like serum sickness [4].
Autoimmune phenomena are common in leishmaniasis 
which could be related to polyclonal B-cell activation, molecu-
lar mimicry between microbial and host antigens, and altered-
reduced regulatory and suppressor T cell functions [4,5]. As a 
consequence of these disturbances, several autoantibodies ap-
pear in the sera of patients with VL, albeit, in most cases ac-
companying clinical manifestations are lacking [5]. On the 
other hand, there are several reports on concurrent or mas-
querading presentations with autoimmune diseases, particu-
larly systemic lupus erythematosus (SLE), rheumatoid arthritis, 
and cryoglobulinemia in the literature [6-8]. Autoimmune 
hepatitis (AIH) is also reported [9]. However, VL resembling 
AIH and primary biliary cirrhosis (PBC) overlap hepatitis has 
not been described before. Herein, we report a case of VL with 
clinical and laboratory features mimicking AIH, PBC overlap 
hepatitis, and SLE. 
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Abstract: Visceral leishmaniasis (VL) is a life-threatening infection caused by Leishmania species. In addition to typical clin-
ical findings as fever, hepatosplenomegaly, and cachexia, VL is associated with autoimmune phenomena. To date, VL 
mimicking or exacerbating various autoimmune diseases have been described, including systemic lupus erythematosus 
(SLE), rheumatoid arthritis, and autoimmune hepatitis (AIH). Herein, we presented a patient with VL who had overlapping 
clinical features with SLE, AIH, as well as antimitochondrial antibody (AMA-M2) positive primary biliary cirrhosis.  
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CASE RECORD
A 26-year-old female patient referred to the rheumatology 
department with complaints of anorexia, malaise, weight loss, 
joint swelling, and low grade fever. She was living in a Mediter-
ranean region of Turkey. Her past history was notable for pho-
tosensitivity, oral ulcers, and possible thalassemia trait. On ad-
mission, her physical examination was significant for erythema 
and symmetrical arthritis at ankles, wrists, and hand joints. The 
spleen was palpated 10 cm below the costal margin, and the 
liver had a longitudinal size of 15 cm. Erythrocyst sedimenta-
tion rate (ESR) and C- reactive protein was 65 and 19.9 mg/L, 
respectively. Complete blood count revealed hemoglobin 10.2 
gr/dl, mean corpuscular volume 69 fl, leukocyte 4,000/mm
3, 
and platelet 157,000/mm
3. Other pertinent laboratory data 
was as follows: creatinine 0.7 mg/dl (Normal=0.5-1.2), ala-
nine aminotransferase 46 U/L (ALT, Normal<40), aspartate 
aminotransferase 51 U/L (AST, Normal<40), alkaline phos-
phatase 67 U/L (ALP, N=53-141), gama-glutamyl transferase 
17 U/L (GGT, N=0-50), albumin 3.2 g/dl, globulin 6.9 g/dl, 
and lactate dehydrogenase 236 U/L (N=125-243). Her labo-
ratory investigation was positive for anti-nuclear antibody im-
munofluorescence (ANA-IFA), anti-smooth muscle antibody 
(ASMA), and Coombs tests on previous referral center. Repeat-
ed ANA was strongly positive as well as antimitochondrial 
(AMA-M2) antibodies and Coombs tests. Rheumatoid factor 
(RF) was 123 IU/ml (N<20). Liver kidney microsomal (anti-
LKM), anti-cytosolic liver (LC-1), antisoluble liver/liver-pan-
creas (SLA/LP), ASMA, anti-ENA, ds-DNA tests were negative. 
Serum C3 and C4 were within normal limits. IgG was 5,810 
mg/dl (N=751-1,560) with a polyclonal pattern. A liver biop-
sy was performed to rule out autoimmune hepatitis. Histologi-
cal examination of the liver biopsy revealed robust plasma cell 
and lymphocyte infiltrations in the sinusoidal areas, and peri-
ductal and portal small granuloma formation. Histochemical-
ly, plasma cells, which were stained for Methyl Grün Pyronine 
(MGP), were found to act as a dominant feature among the in-
flammatory infiltrates in the liver. This finding also supported 
and raised the suspicion of autoimmune hepatitis-PBC over-
lap (Fig. 1A, B). 
Prednisone was started at a dose of 1 mg/kg under a pre-
sumptive diagnosis of SLE/AIH with a rapid clinical improve-
ment on arthritis, fever, malaise and general condition, liver 
function tests, acute phase response, and hypergammaglobu-
linemia. Therefore, azathioprine 50 mg b.i.d. was added to the 
therapy with tapering steroid dose. A few weeks after the im-
munosuppression, her leukocyte and platelet counts began to 
fall gradually, reaching 1,000/mm
3 and 14,000/mm
3, respec-
tively. Azathiopurine was discontinued. The patient was trans-
ferred to the infectious diseases department with the diagnosis 
of neutropenic fever. An empirical therapy with cefoperazone 
sulbactam was started. After 4 days, teicoplanin and flucon-
azole were added to the treatment because of urinary infection 
caused by enterococci and Candida albicans. Although, against 
this appropriate treatment, her condition got worse, fever con-
tinued, and neutropenia and thrombocytopenia persisted. A 
bone marrow aspiration and biopsy were performed to rule 
out possible bone marrow pathology. 
The bone marrow smears revealed macrophages with nu-
merous Leishmania amastigotes (Fig. 2). The bone marrow bi-
Fig. 1. (A) Indirect cholestatic features with lobular confluent ne-
crosis (H&E stain, ×200). (B) Plasma cells as a dominant com-
ponent of inflammation in the liver (MGP, ×400)
A B
Fig. 2. A bone marrow smear showing macrophages containing 
numerous Leishmania amastigotes (May-Grunwald/Giemsa stain, 
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opsy also showed Leishmania parasites within macrophages. 
The amastigote tissue forms were seen when her liver biopsy 
was re-evaluated (Fig. 3). Leishmania IgG was found positive at 
a 1/1,280 titer in her serum specimen by indirect immunoflu-
orescent assay. High dose (4 mg/kg/day) intravenous liposo-
mal amphotericin B was given on days 1 to 5 and 10, 17, 24, 
31, and 38 days [10]. Then, her fever resolved, and general con-
ditions greatly improved with the exception of neutropenia. 
After a dose of granulocyte colony-stimulating factor, her neu-
trophil count also reached to a normal level. No other compli-
cations were observed in the duration of the treatment.
On her follow-up examination at 6 months after amphoter-
icin therapy, she was in good clinical condition with free of any 
complaints and had normal blood counts, biochemical ana-
lyzes, and normal gammaglobulin levels. ASMA become nega-
tive, and ANA and AMA-M3 tests remained weak and strong 
positives, respectively. 
DISCUSSION
Leishmaniasis is a parasitic disease, which is transmitted to 
humans by sandflies in endemic areas. VL is considered en-
demic in tropical and subtropical regions (Bangladesh, India, 
Nepal, Sudan, and Brazil) in the world. However, in other coun-
tries, it is detected in a few cases. In Turkey, VL is seen mainly 
in the Aegean, Mediterranean, and Central Anatolia regions, 
and Leishmania infantum is the most responsible agent for the 
human diasese. Children were at a higher risk of infection, and 
only a few adult cases of VL were reported from Turkey [9,11-
13]. 
Our patient was living in an endemic region. VL is a dissem-
inated intracellular infection with a fatality rate of as high as 
90%, unless treated. Classic clinical features include high fever, 
severe anorexia, and marked hepatosplenomegaly. Laboratory 
tests frequently show pancytopenia, marked eosinopenia, a 
relative lympho-monocytosis and hypergammaglobulinemia 
with hypoalbuminemia, and occasionally evidence of liver 
damages with raised liver enzymes. The diagnosis is based on 
a combination of demographic, clinical, laboratory findings, 
and confirmation of the disease via demonstration of amasti-
gote tissue forms of parasites or Leishmania-specific immuno-
logical tests [1,2]. VL remains asymptomatic or subclinical in 
many cases, or can follow an acute, subacute, or chronic course. 
Chronic VL results in delays in diagnosis due to subtle or atyp-
ical presentations [1]. 
Autoimmune phenomena are common in Leishmania infec-
tions. This might be due to a release of high amounts of self 
antigens as a result of tissue destruction caused by the parasite. 
Release of tissue antigens may stimulate the autoreactivity and 
autoantibody production. Another possible mechanism is al-
tered host immune responses caused by Leishmania parasites. 
Both T and B cells are affected by VL [14]. VL causes polyclonal 
B cell activation independent of T cells through mitogen acti-
vation or stimulation of cytokines by other immune cells [4,5]. 
B cell hyperactivation results in severe hypergammaglobuline-
mia observed in VL. Finally, as demonstrated previously, there 
are some molecular mimicry between Leishmania antigens and 
host antigens such as ribosomal phosphoproteins expressed 
on parasites, causing cross-reactivity [5,14]. 
Reported autoimmune diseases that were mimicked or exac-
erbated by leishmaniasis are SLE, AIH, rheumatoid arthritis, 
polyarteritis nodosa, cryoglobulinemic vasculitis, autoimmune 
hemolytic anemia, and Ewan’s syndrome [6-9,11,12]. All of 
them, particularly SLE and AIH have clinical and laboratory 
features undistinguishable from VL that makes confusion. More-
over, many autoantibodies are formed in VL, even disease spe-
cific ones, including RF, anticitrulline, ANA, ds-DNA, ASMA, 
anti-Ro, anti-La, anti-Sm, anti-cardiolipin, and anti-platelet an-
tibodies [4,5,14,15]. Positivity of one or more of these tests 
with vague clinical presentations may be misinterpreted as au-
toimmune disorders. 
A correct diagnosis of VL was tricky in our patient because 
of presentation which was very similar to the autoimmune liv-
er disease and SLE. Though the liver enzymes are frequently 
elevated in leishmaniasis, positive autoimmune laboratory tests 
and liver biopsy reported as consistent with AIH-PBC overlap 
Fig. 3. Clusters of leishmanias within the cytoplasm of Kupffer 
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led us to consider autoimmune overlap hepatitis and SLE as 
the cause. Rapid response to prednisone further supported 
AIH/SLE diagnosis. Hematological manifestations appeared 
later in the clinical course and that was thought as an azathio-
prine side-effect. However, discontinuation of this drug and 
escalating prednisone dose did not improve clinical pictures, 
and the patient was re-evaluated revealing VL diagnosis. 
PBS or its serological marker AMA-M2 positivity has not 
been reported in patients with VL, to the best of our knowl-
edge. Persistently high titers of AMA-M2 even 6 months after 
the appropriate treatment could be consistent with true diag-
nosis of PBS in our patient which might be concurrent with 
VL. However, re-biopsy was refused by the patient.
Leishmaniasis is characterized by multiple immunological 
abnormalities and protean clinical manifestations that may be 
misinterpreted as various autoimmune diseases. Moreover, 
early responses to immunosuppressives may masquerade clin-
ical pictures of VL. Treatment of autoimmune diseases may 
worsen the disease and even cause a fatal outcome in VL pa-
tients. Therefore, in case of atypical presentations or treatment 
failure in autoimmune diseases, leishmaniasis should be con-
sidered and ruled out. 
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